Pelthos Therapeutics Inc. (PTHS) Financial Ratios
3 years of historical data (2022–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
N/A
—
5yr avg: N/A
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PTHS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pelthos Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Market Cap | $15M | — | — | — |
| Enterprise Value | $17M | — | — | — |
| P/E Ratio → | -1.91 | — | — | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | — | — | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PTHS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
PTHS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ROE | — | — | — | — |
| ROA | -1085.7% | -1085.7% | -9745.9% | -4464.2% |
| ROIC | — | — | — | — |
| ROCE | — | — | — | — |
PTHS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $2M ($2M total debt minus $513443 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Debt / Equity | — | — | — | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -9.63 | -9.63 | -13.23 | -16.51 |
PTHS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.34x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.01x to 0.34x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Current Ratio | 0.34 | 0.34 | 0.01 | 0.01 |
| Quick Ratio | 0.34 | 0.34 | 0.01 | 0.01 |
| Cash Ratio | 0.13 | 0.13 | 0.01 | 0.01 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
PTHS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pelthos Therapeutics Inc. returns 1.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 1.1% | — | — | — |
| Total Shareholder Yield | 1.1% | — | — | — |
| Shares Outstanding | — | $587620 | $576752 | $576752 |
Peer Comparison
Compare PTHS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PTHSYou | $15M | -1.9 | — | — | — | — | — | — | — |
 COLL | $1B | 22.7 | 4.8 | 3.9 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 MCK | $92B | 29.2 | 18.7 | 17.6 | 3.5% | 1.2% | — | 540.6% | 1.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 3 years · Updated daily
See PTHS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTHS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTHS vs COLL
Side-by-side business, growth, and profitability comparison vs Collegium Pharmaceutical, Inc..
Start ComparisonPTHS — Frequently Asked Questions
Quick answers to the most common questions about buying PTHS stock.
What is Pelthos Therapeutics Inc.'s P/E ratio?
Pelthos Therapeutics Inc.'s current P/E ratio is -1.9x. This places it at the 50th percentile of its historical range.
Is PTHS stock overvalued?
Based on historical data, Pelthos Therapeutics Inc. is trading at a P/E of -1.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.